Investor Type | Firm |
Type of Fund | Venture Capital Fund |
Industries | Software (Web Marketplace Saas..) • IT (& TMT) • Media • Education • FinTech (& Financials services) • Hardware (& Manufacturing) • IoT (& Wearables) • Real Estate (& Construction) • Investment Management |
Stages | Seed, Startup, Early Stage, Expansion, Later Stage |
Investing | United States • Germany • France • Sweden • Switzerland • Denmark • Austria • Finland • Norway |
Investment Range | €500,000 - €10,000,000 |
Assets Under Management | €220,000,000 |
Nexit Ventures Oy, rebranded as Creathor Ventures, is a venture capital firm headquartered in Bad Homburg, Germany, with additional presence in Switzerland. With a history dating back to 1984, they have been committed to backing the creators of the future, especially in the realms of technology and science. The firm manages funds totaling approximately €230 million, including predecessor funds, and their specialty lies in equity investments. Creathor Ventures targets a range of industries: Software, IT, Media, Education, FinTech, Hardware, IoT, Real Estate, and Investment Management. The firm's investment focus encompasses various stages of a company’s lifecycle, including Seed, Startup, Early Stage, Expansion, and Later Stage, with a minimum investment threshold of €500,000 and a maximum of €10,000,000. With assets under management totaling around €220 million, they provide not just financial support but also leverage their expertise and experience to ensure the success of their portfolio companies. Over their extensive operating history, they have funded a significant number of tech companies as well as healthcare businesses. Their portfolio includes innovative and impactful companies such as Allthings Technologies, Blueprint Genetics, EchoRing by R3, HeyJobs, Phenex Pharmaceuticals, and Wunderflats. Creathor Ventures views themselves as partners with the best and brightest, and they boast a track record of successful exits, including seven billion-dollar companies. Their approach is reflected through their robust support system for entrepreneurs, regular sharing of updates and opinions on industry trends, and the facilitation of connections within their network. True to this ethos, they have provided additional funding for CryoTherapeutics and supported the successful exit of Cube Biotech GmbH, showcasing their active role in the growth and success of their investments.